Immunology Core
Immunology Core
批准号:
8379257
负责人:
Chien-Fu Hung
金额:
$21.75万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
Advisory CommitteesBiological AssayBiometryCD8B1 geneCellular AssayCellular ImmunityClinical TrialsConflict of InterestCritiquesDataData AnalysesData Storage and RetrievalDevelopmentEnsureEnzyme-Linked Immunosorbent AssayFlow CytometryFundingFutureGardasilGoalsHPV-High RiskHuman PapillomavirusHuman ResourcesHuman papilloma virus infectionHuman papillomavirus 16Human papillomavirus 6Humoral ImmunitiesImmune responseImmunoglobulin GImmunologyImmunology procedureIn VitroIndividualInstructionInterferon Type IILabelLaboratoriesLymphocyteMalignant neoplasm of cervix uteriMeasuresOutcome MeasurePathologyPeptidesPerformancePeripheral Blood Mononuclear CellPhasePhenotypePreventionProceduresProteinsProtocols documentationQuality ControlReagentResearch PersonnelResourcesSamplingSerumServicesSpecimenStaining methodStainsStandardizationTestingTissuesTrainingVaccinatedVaccine AntigenVaccinesVirus-like particleWorkassay developmentbasecytokinedata acquisitiondata managementdatabase structuredesignenzyme linked immunospot assaygood laboratory practicehead-to-head comparisonimmunogenicityinterestnovelnovel vaccinesprimary outcomeprogramsresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The Immunology Core (Core D) is a new core that was established after discussion by the SPORE Internal and External Advisory Committees and in response to the previous critique of our renewal application. The principal goal of the Core is to establish standardized assays of cellular and humoral immune responses to the vaccines being developed and tested by the four projects of the SPORE program.
Standardization will be achieved by use of uniform reagents and protocols, trained personnel and stringent quality control measures. Centralized performance of these assays will facilitate head-to-head comparisons of vaccines that use the same primary immunological outcome measures and provide for efficient use of resources. Because some SPORE investigators have a financial interest in the vaccines that are being
tested, assessment of immunogenicity by an independently directed laboratory will also allay concerns over possible conflicts of interest. The services provided by the Core to the individual projects are the following.
For Project I, the assays include serum IgG-specific HPV 16 L1 virus like particle (VLP) enzyme linked immunosorbent assay (ELISA) and HPV 16, 31 and 33 in vitro pseudovirion neutralization assays. The latter 2 types are included to assess possible cross neutralization of genetically related types. For Project II, the Core will perform an ELISA to detect serum IgG directed against the vaccinogen, HPV L2 11-200x3 protein and in vitro pseudovirion neutralization assays for HPV 6 and 11 and 15 high risk HPV types. For the subset of subjects vaccinated with Gardasil, serum samples will be tested in the HPV 16 VLP ELISA and HPV 6, 11, 16, 18, 31, 33 and 45 pseudovirion neutralization assays. For Projects III and IV, the Core will perform IFN- gamma ELISPOT assays on unfractionated peripheral blood mononuclear cells (PBMC) following overnight stimulation with pools of E6 or E7 peptides. The CD8+ and CD4 + phenotype of the responding lymphocytes
will be confirmed by intracellular cytokine staining and flow cytometry. Secondary immunologic assays, assays specific to an individual project and novel immunologic assay development will be performed and perfected by the investigators within the individual projects and only transferred to the Immunology Core when fully optimized and standardized. The Immunology Core will interact extensively with the individual
projects as well as the Tissue/Pathology Core (Core C), which will provide specimens, and the Biostatistlcs/Data Management Core (Core B), which will perform data analyses.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel strategy combined with targeted radiation therapy unleashes potent antitumor immunity in HPV + head and neck cancer
-
批准号:10285000
-
项目类别:
-
资助金额:$22.97万
-
财政年份:2021
-
负责人:Chien-Fu Hung
-
依托单位:
Novel strategy combined with targeted radiation therapy unleashes potentantitumor immunity in HPV + head and neck cancer
-
批准号:10418815
-
项目类别:
-
资助金额:$18.76万
-
财政年份:2021
-
负责人:Chien-Fu Hung
-
依托单位:
Novel immunotherapeutic regimen combining the dendritic cell expansion power of Albumin-Flt3L and inflammatory cues of Salmonella
-
批准号:10206098
-
项目类别:
-
资助金额:$24.56万
-
财政年份:2020
-
负责人:Chien-Fu Hung
-
依托单位:
Novel immunotherapeutic regimen combining the dendritic cell expansion power of Albumin-Flt3L and inflammatory cues of Salmonella
-
批准号:10041196
-
项目类别:
-
资助金额:$20.47万
-
财政年份:2020
-
负责人:Chien-Fu Hung
-
依托单位:
Mouse modeling of HPV infection
-
批准号:10304917
-
项目类别:
-
资助金额:$58.26万
-
财政年份:2018
-
负责人:Chien-Fu Hung
-
依托单位:
Mouse modeling of HPV infection
-
批准号:10535434
-
项目类别:
-
资助金额:$58.16万
-
财政年份:2018
-
负责人:Chien-Fu Hung
-
依托单位:
Mouse modeling of HPV infection
-
批准号:10054175
-
项目类别:
-
资助金额:$59.54万
-
财政年份:2018
-
负责人:Chien-Fu Hung
-
依托单位:
Innovative Strategy to Generate Antigen-Specific Cytotoxic Lymphocytes
-
批准号:8878679
-
项目类别:
-
资助金额:$17.62万
-
财政年份:2015
-
负责人:Chien-Fu Hung
-
依托单位:
Innovative Strategy to Generate Antigen-Specific Cytotoxic Lymphocytes
-
批准号:9110913
-
项目类别:
-
资助金额:$21.14万
-
财政年份:2015
-
负责人:Chien-Fu Hung
-
依托单位:
Molecular pathogenesis and host response following persistent E6/E7 expression
-
批准号:8619069
-
项目类别:
-
资助金额:$20.25万
-
财政年份:2014
-
负责人:Chien-Fu Hung
-
依托单位:
Immunology Core
-
批准号:7727559
-
项目类别:
-
资助金额:$18.41万
-
财政年份:2009
-
负责人:Chien-Fu Hung
-
依托单位:
Electroporation delivery of pNGVL4aCRTE6E7L2 DNA for treatment of HPV16+ CIN2/3 patients
-
批准号:10005176
-
项目类别:
-
资助金额:$29.25万
-
财政年份:2003
-
负责人:Chien-Fu Hung
-
依托单位:
Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporation
-
批准号:8747872
-
项目类别:
-
资助金额:$24.11万
-
财政年份:2003
-
负责人:Chien-Fu Hung
-
依托单位:
Immunology Core
-
批准号:8326157
-
项目类别:
-
资助金额:$21.44万
-
财政年份:--
-
负责人:Chien-Fu Hung
-
依托单位:
Immunology Core
-
批准号:8537836
-
项目类别:
-
资助金额:$20.36万
-
财政年份:--
-
负责人:Chien-Fu Hung
-
依托单位:
Immunology Core
-
批准号:8182337
-
项目类别:
-
资助金额:$21.09万
-
财政年份:--
-
负责人:Chien-Fu Hung
-
依托单位:
Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporation
-
批准号:9143706
-
项目类别:
-
资助金额:$24.13万
-
财政年份:--
-
负责人:Chien-Fu Hung
-
依托单位:
海外基金